Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Broad coverage extended to Japan and related regions
SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”
Related news for (ANIX)
- Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
- Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
- MoBot alert highlights: NASDAQ: XTLB, NASDAQ: QTTB, NASDAQ: BIAF, NASDAQ: ANIX, NASDAQ: NERV (10/07/25 07:00 PM)
- MoBot’s Stock Market Highlights – 10/07/25 03:00 PM
- 24/7 Market News Snapshot 07 October, 2025 – Anixa Biosciences, Inc. (NASDAQ:ANIX)
